Immunoinhibitory checkpoint deficiency in medium & large vessel vasculitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 6, 2017, Pages E970-E979

  Zhang, Hui ^a   Watanabe, Ryu ^a   Berry, Gerald J ^a   Vaglio, Augusto ^b   Liao, Yaping Joyce ^a   Warrington, Kenneth J ^c   Goronzy, Jörg J ^a   Weyand, Cornelia M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Mayo Clinic   (United States)

Author keywords

Autoimmunity; Immune checkpoint; PD 1; T cells; Vasculitis

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 21; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TRANSCRIPTOME; CYTOKINE;

AGED; ARTICLE; AUTOIMMUNITY; BLOOD VESSEL BIOPSY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; EX VIVO STUDY; FEMALE; GIANT CELL ARTERITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TEMPORAL ARTERY; VASCULITIS; ANIMAL; ARTERY; CELL CULTURE; GENE EXPRESSION PROFILING; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; SCID MOUSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; ARTERIES; B7-H1 ANTIGEN; CELLS, CULTURED; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GIANT CELL ARTERITIS; HUMANS; INFLAMMATION; MALE; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85011650396     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1616848114     Document Type: Article

References (63)

1. Weyand CM, et al. (1994) Distinct vascular lesions in giant cell arteritis share identical T cell clonotypes. J Exp Med 179(3):951-960.
2. Grunewald J, et al. (1994) CD4+ and CD8+ T cell expansions using selected TCR V and J gene segments at the onset of giant cell arteritis. Arthritis Rheum 37(8):1221-1227.
3. Weyand CM, Younge BR, Goronzy JJ (2011) IFN-γ and IL-17: The two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol 23(1):43-49.
4. Ciccia F, et al. (2015) Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. Rheumatology (Oxford) 54(9):1596-1604.
5. Weyand CM, Wagner AD, Björnsson J, Goronzy JJ (1996) Correlation of the topographical arrangement and the functional pattern of tissue-infiltrating macrophages in giant cell arteritis. J Clin Invest 98(7):1642-1649.
6. Weyand CM, Goronzy JJ (1999) Arterial wall injury in giant cell arteritis. Arthritis Rheum 42(5):844-853.
7. Rittner HL, et al. (1999) Tissue-destructive macrophages in giant cell arteritis. Circ Res 84(9):1050-1058.
8. Dal Canto AJ, Swanson PE, O'Guin AK, Speck SH, Virgin HW (2001) IFN-gamma action in the media of the great elastic arteries, a novel immunoprivileged site. J Clin Invest 107(2):R15-R22.
9. Pryshchep O, Ma-Krupa W, Younge BR, Goronzy JJ, Weyand CM (2008) Vessel-specific Toll-like receptor profiles in human medium and large arteries. Circulation 118(12): 1276-1284.
10. Pober JS, Tellides G (2012) Participation of blood vessel cells in human adaptive immune responses. Trends Immunol 33(1):49-57.
11. Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4(5):336-347.
12. Nishimura H, Honjo T (2001) PD-1: An inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22(5):265-268.
13. Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99(19):12293-12297.
14. Hamid O, et al. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369(2):134-144.
15. Garon EB, et al.; KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018-2028.
16. Brahmer JR, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455-2465.
17. Nishimura H, Nose M, Hiai H, Minato N, Honjo T (1999) Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11(2):141-151.
18. Nishimura H, et al. (2001) Autoimmune dilated cardiomyopathy in PD-1 receptordeficient mice. Science 291(5502):319-322.
19. Keir ME, et al. (2006) Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203(4):883-895.
20. Latchman YE, et al. (2004) PD-L1-deficient mice show that PD-L1 on T cells, antigenpresenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci USA 101(29):10691-10696.
21. Hirata S, et al. (2005) Prevention of experimental autoimmune encephalomyelitis by transfer of embryonic stem cell-derived dendritic cells expressing myelin oligodendrocyte glycoprotein peptide along with TRAIL or programmed death-1 ligand. J Immunol 174(4):1888-1897.
22. Francisco LM, et al. (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206(13):3015-3029.
23. McAlees JW, et al. (2015) Differential control of CD4(+) T-cell subsets by the PD-1/PDL1 axis in a mouse model of allergic asthma. Eur J Immunol 45(4):1019-1029.
24. Ma-Krupa W, et al. (2004) Activation of arterial wall dendritic cells and breakdown of self-Tolerance in giant cell arteritis. J Exp Med 199(2):173-183.
25. Weyand CM, et al. (2005) Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci 1062:195-208.
26. Wen Z, et al. (2016) NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. J Clin Invest 126(5):1953-1967.
27. Piggott K, et al. (2011) Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis. Circulation 123(3):309-318.
28. Wagner AD, Björnsson J, Bartley GB, Goronzy JJ, Weyand CM (1996) Interferongamma- producing T cells in giant cell vasculitis represent a minority of tissue-infiltrating cells and are located distant from the site of pathology. Am J Pathol 148(6): 1925-1933.
29. Slobodin G, et al. (2007) Biopsy-negative giant cell arteritis: Does anti-CD83 immunohistochemistry advance the diagnosis? Eur J Intern Med 18(5):405-408.
30. Freeman GJ, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027-1034.
31. Dong H, et al. (2002) Tumor-Associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8(8):793-800.
32. Brown JA, et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170(3):1257-1266.
33. Weyand CM, Goronzy JJ (2013) Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol 9(12):731-740.
34. Kaiser M, Weyand CM, Björnsson J, Goronzy JJ (1998) Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 41(4):623-633.
35. Lozano E, Segarra M, García-Martínez A, Hernández-Rodríguez J, Cid MC (2008) Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 67(11):1581-1588.
36. Kaiser M, Younge B, Björnsson J, Goronzy JJ, Weyand CM (1999) Formation of new vasa vasorum in vasculitis. Production of angiogenic cytokines by multinucleated giant cells. Am J Pathol 155(3):765-774.
37. Makkuni D, et al. (2008) Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology (Oxford) 47(4):488-490.
38. Waterhouse P, et al. (1995) Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238):985-988.
39. Dong H, et al. (2004) B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes. Immunity 20(3):327-336.
40. Wilde B, et al. (2012) Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 51(7):1188-1197.
41. Goldstein BL, Gedmintas L, Todd DJ (2014) Drug-Associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 66(3):768-769.
42. Vanneman M, Dranoff G (2012) Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 12(4):237-251.
43. Hokey DA, et al. (2008) Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur J Immunol 38(5): 1435-1445.
44. Terrier B, et al. (2012) Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 64(6):2001-2011.
45. Francisco LM, Sage PT, Sharpe AH (2010) The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219-242.
46. Parry RV, et al. (2005) CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25(21):9543-9553.
47. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98(24):13866-13871.
48. Delgoffe GM, et al. (2009) The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30(6):832-844.
49. Chi H (2012) Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 12(5):325-338.
50. Cooley BC, et al. (2014) TGF-β signaling mediates endothelial-To-mesenchymal transition (EndMT) during vein graft remodeling. Sci Transl Med 6(227):227ra34.
51. Cooke VG, et al. (2012) Pericyte depletion results in hypoxia-Associated epithelial-Tomesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21(1):66-81.
52. Barber DL, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682-687.
53. Day CL, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109):350-354.
54. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG (2015) T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523(7562):612-616.
55. Fife BT, Bluestone JA (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 224:166-182.
56. Mühlbauer M, et al. (2006) PD-L1 is induced in hepatocytes by viral infection and by interferon-Alpha and -gamma and mediates T cell apoptosis. J Hepatol 45(4):520-528.
57. Schreiner B, et al. (2004) Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: Relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol 155(1-2):172-182.
58. Mazanet MM, Hughes CC (2002) B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol 169(7):3581-3588.
59. Kinter AL, et al. (2008) The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 181(10): 6738-6746.
60. Weyand CM, et al. (1997) Disease patterns and tissue cytokine profiles in giant cell arteritis. Arthritis Rheum 40(1):19-26.
61. Weyand CM, Goronzy JJ (2003) Medium-And large-vessel vasculitis. N Engl J Med 349(2):160-169.
62. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM (2010) Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 121(7):906-915.
63. Shirai T, et al. (2016) The glycolytic enzyme PKM2 bridges metabolic and inflammatory dysfunction in coronary artery disease. J Exp Med 213(3):337-354.